Search
Revising the ICH Guidelines on Clinical Trials
The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.
Read moreEHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation
To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).
Read moreLymphomas from A to Z
Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomas on March 10-12, 2017 in Barcelona, Spain.
Read moreMore than science: the European Affairs program at EHA2023
To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.
Read moreHighlights of Past EHA (HOPE) Asia 2023
EHA joined forces with the Indian Society of Hematology & Blood Transfusion (ISHBT) to organize the 5th edition of the Highlights of Past EHA (HOPE) Asia 2023 meeting.
Read moreHemaSphere Editorial Board
Editor-in-Chief
Jan Cools, Belgium
Deputy Editor-in-Chief
Claire Harrison, United Kingdom
Associate Editors
Stephen Ansell, USA
Martin Dreyling, Germany
Jeroen Eikenboom, The Netherlands
Adele Fielding, United Kingdom
Paolo Ghia, Italy
Simon Hallam, United Kingdom
Robert Hills, United Kingdom
Steffen Koschmieder, Germany
Martina Mückenthaler, Germany
Paula Rodríguez Otero, Spain
Juerg Schwaller, Switzerland
Francesca Vinchi, USA
Scientific Editors
Charles de Bock,…